Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07765524
What this trial is testing

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis

Who this might be right for
Primary Light Chain (AL) Amyloidosis
Shenzhen Fosun Kairos Biotechnology Co., Ltd. 32
Testing effectiveness (Phase 2)UnknownNCT03118180
What this trial is testing

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Who this might be right for
Lymphoma
Zhejiang University 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04637503
What this trial is testing

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Who this might be right for
Neuroblastoma
Shenzhen Geno-Immune Medical Institute 100
Testing effectiveness (Phase 2)Ended earlyNCT02794246
What this trial is testing

CART-19 Post-ASCT for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 6
Testing effectiveness (Phase 2)Looking for participantsNCT06316856
What this trial is testing

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Who this might be right for
T-Cell Acute Lymphocytic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital 54
Early research (Phase 1)Looking for participantsNCT06087341
What this trial is testing

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma

Who this might be right for
Advanced Sarcoma
Antonio Pérez Martínez 18
Testing effectiveness (Phase 2)Looking for participantsNCT04844866
What this trial is testing

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH 213
Testing effectiveness (Phase 2)UnknownNCT02742727
What this trial is testing

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Who this might be right for
Acute Myeloid LeukemiaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaT-cell Prolymphocytic Leukemia+6 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)UnknownNCT04762485
What this trial is testing

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Who this might be right for
T Lymphoblastic Leukemia/LymphomaMixed Phenotype Acute LeukemiaAcute Myeloid Leukemia
The First Affiliated Hospital of Soochow University 20
Early research (Phase 1)Ended earlyNCT05094206
What this trial is testing

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Who this might be right for
B-cell Non Hodgkin LymphomaB-cell Chronic Lymphocytic Leukemia
Medical College of Wisconsin 4
Early research (Phase 1)Study completedNCT04394650
What this trial is testing

CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene 78
Early research (Phase 1)Looking for participantsNCT06251544
What this trial is testing

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

Who this might be right for
Breast CancerTumor, BreastBreast Tumor+5 more
Baylor College of Medicine 27
Early research (Phase 1)Looking for participantsNCT06865664
What this trial is testing

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

Who this might be right for
Rhabdomyosarcoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06675864
What this trial is testing

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Who this might be right for
Progressive Multiple Sclerosis
Novartis Pharmaceuticals 28
Early research (Phase 1)Study completedNCT02765243
What this trial is testing

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma

Who this might be right for
NeuroblastomaEffects of Immunotherapy
Zhujiang Hospital 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT06384976
What this trial is testing

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis+1 more
Kyverna Therapeutics 120
Not applicableStudy completedNCT05130489
What this trial is testing

CAR T Cell Therapy Related Cardiovascular Outcomes

Who this might be right for
Cardiovascular DiseasesB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma Refractory+5 more
University College London Hospitals 150
Testing effectiveness (Phase 2)Looking for participantsNCT06794008
What this trial is testing

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)+6 more
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05234190
What this trial is testing

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Who this might be right for
Rejection; Transplant, LiverLiver FailureLiver Diseases
Quell Therapeutics Limited 33
Very early researchNot Yet RecruitingNCT07727668
What this trial is testing

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaRelapsed/Refractory Multiple Myeloma
Shambavi Richard 22
Next Page